Multiple Myeloma Resource Center
Welcome to the Multiple Myeloma Resource Center

A collection of recently published journal articles textbooks, images, and review questions focusing on Multiple Myeloma.

Featured Content
New Article: Molecular Abnormalities & Biomarkers of Progression in Smoldering Multiple Myeloma

A study conducted by researchers with the Dana-Farber Cancer Institute, performed a genomic test of bone marrow tissue identifying specific biomarkers in patients with smoldering multiple myeloma (SMM) who may be at a high risk of developing the symptomatic form of the disease with end organ damage.

Read Article

Downloadable Chart

The Multiple Myeloma chart provides an overview of cancer of the plasma cells in bone marrow. The chart contains large annotated illustrations, easy-to-read tables and bulleted lists that simplify and condense complex material in an accessible manner.

  • A brief definition of multiple myeloma followed by bulleted lists of risk factors
  • Signs and Symptoms describe common patient complaints
  • Diagnosis/Screening section includes a short succinct list
  • Treatment section includes a list of drug treatments and outlines Stages I, II, and III

Download Now

Article

For the last 4-5 years, Irene Ghobrial, MD, and researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital have focused their efforts on trying to understand mechanisms of disease progression from early precursor conditions, like monoclonal gammopathy of unknown significance (MGUS), to myeloma.

Read Article

New Article: Encouraging Findings for Belantamab Mafadotin in Treating Multiple Myeloma

Belantamab mafadotin is an immunoconjugate targeting B-cell maturation antigen, a pathway shown to be important for the growth and survival of myeloma cells. The drug is currently under investigation for the treatment of multiple myeloma, the second most common blood cancer.

Read Article

Quiz

Originally Published in The Bethesda Review of Clinical Oncology - 

In patients with newly diagnosed multiple myeloma receiving initial ther-apy with a combination of bortezomib, lenalidomide, and dexametha-sone, addition of autologous stem cell transplant is associated with

Take the Quiz

Article

Results from the ongoing KarMMa-real world (RW) study revealed that idecabtagene vicleucel (ide-cel; bb2121) demonstrates deep, durable responses and significantly improved progression-free survival (PFS) in patients with relapsed and refractory multiple myeloma (RRMM). This work was presented at the 2020 ASCO Annual Meeting (Abstract 8525).

Read Article

Case

Originally Published in The Bethesda Review of Clinical Oncology -

A 68- year- old lady is found to have IgA lambda M- spike of 3.1 g/ dL on evaluation for lower back pain. Her hemoglobin is 12 g/ dL, MCV 87 fL, and platelets 212 × 109/ mm3, and serum calcium and creatinine are nor-mal. A skeletal survey reveals no lytic lesions.

Read the Case and take the Quiz